112 results on '"Fonge, Humphrey"'
Search Results
2. Biodistribution of nanodiamonds is determined by surface functionalization
3. Effectiveness of 225Ac-Labeled Anti-EGFR Radioimmunoconjugate in EGFR-Positive Kirsten Rat Sarcoma Viral Oncogene and BRAF Mutant Colorectal Cancer Models.
4. Efficacy of [67Cu]Cu-EB-TATE Theranostic Against Somatostatin Receptor Subtype-2-Positive Neuroendocrine Tumors.
5. Efficacy of [67Cu]Cu-EB-TATE Theranostic Against Somatostatin Receptor Subtype-2–Positive Neuroendocrine Tumors
6. Effectiveness of225Ac-Labeled Anti-EGFR Radioimmunoconjugate in EGFR-Positive Kirsten Rat Sarcoma Viral Oncogene and BRAF Mutant Colorectal Cancer Models
7. Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety
8. Evaluation of nimotuzumab Fab2 as an optical imaging agent in EGFR positive cancers
9. Development and preclinical evaluation of cixutumumab drug conjugates in a model of insulin growth factor receptor I (IGF-1R) positive cancer
10. A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
11. Evaluation of nimotuzumab Fab2 as an optical imaging agent in EGFR positive cancers.
12. Engineering of a Fully Human Anti-MUC-16 Antibody and Evaluation as a PET Imaging Agent
13. Simultaneous Imaging and Therapy Using Epitope-Specific Anti-Epidermal Growth Factor Receptor (EGFR) Antibody Conjugates
14. 3p-C-NETA: A versatile and effective chelator for development of Al18F-labeled and therapeutic radiopharmaceuticals
15. Concussion/Mild Traumatic Brain Injury (TBI) Induces Brain Insulin Resistance: A Positron Emission Tomography (PET) Scanning Study
16. A 89Zr-labeled lipoplex nanosystem for image-guided gene delivery: design, evaluation of stability and in vivo behavior
17. Additional file 6 of Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety
18. Additional file 1 of Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety
19. Additional file 9 of Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety
20. Additional file 8 of Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety
21. Additional file 4 of Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety
22. Additional file 5 of Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety
23. Additional file 7 of Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety
24. Additional file 3 of Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety
25. Additional file 2 of Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety
26. 3p-C-NETA: A versatile and effective chelator for development of Al18F-labeled and therapeutic.
27. 89Zr-Labeled Domain II-Specific scFv-Fc ImmunoPET Probe for Imaging Epidermal Growth Factor Receptor In Vivo
28. Nimotuzumab Site-Specifically Labeled with 89Zr and 225Ac Using SpyTag/SpyCatcher for PET Imaging and Alpha Particle Radioimmunotherapy of Epidermal Growth Factor Receptor Positive Cancers
29. Production and Semi-Automated Processing of 89Zr Using a Commercially Available TRASIS MiniAiO Module
30. Non-invasive detection and quantification of acute myocardial infarction in rabbits using mono-[123I]iodohypericin µSPECT
31. Next-generation sequencing-guided identification and reconstruction of antibody CDR combinations from phage selection outputs
32. Therapeutic potential of nimotuzumab PEGylated-maytansine antibody drug conjugates against EGFR positive xenograft
33. Preclinical Evaluation of 111In-Labeled PEGylated Maytansine Nimotuzumab Drug Conjugates in EGFR-Positive Cancer Models
34. Near infrared imaging of epidermal growth factor receptor positive xenografts in mice with domain I/II specific antibody fragments
35. A 89Zr-labeled lipoplex nanosystem for image-guided gene delivery: design, evaluation of stability and in vivo behavior
36. Preclinical Evaluation of 111In-labeled PEGylated Maytansine Nimotuzumab Drug.
37. A novel synthetic trivalent single chain variable fragment (tri-scFv) construction platform based on the SpyTag/SpyCatcher protein ligase system
38. 89Zr-nimotuzumab for immunoPET imaging of epidermal growth factor receptor I
39. Evaluation of antibody fragment properties for near-infrared fluorescence imaging of HER3-positive cancer xenografts
40. Near infrared fluorescence imaging of EGFR expressionin vivousing IRDye800CW-nimotuzumab
41. A 89Zr-labeled lipoplex nanosystem for image-guided gene delivery: design, evaluation of stability and in vivo behavior.
42. Development of an Epidermal Growth Factor Derivative with EGFR Blocking Activity
43. Estrone-3-Sulphate, a Potential Novel Ligand for Targeting Breast Cancers
44. Positron Emission Tomographic Imaging of Iodine 124 Anti–Prostate Stem Cell Antigen–Engineered Antibody Fragments in LAPC-9 Tumor–Bearing Severe Combined Immunodeficiency Mice
45. Abstract 3929: Estrone-3-sulphate, a potential novel ligand for targeting breast cancers.
46. 89 Zr-Labeled Domain II-Specific scFv-Fc ImmunoPET Probe for Imaging Epidermal Growth Factor Receptor In Vivo.
47. Nimotuzumab Site-Specifically Labeled with 89 Zr and 225 Ac Using SpyTag/SpyCatcher for PET Imaging and Alpha Particle Radioimmunotherapy of Epidermal Growth Factor Receptor Positive Cancers.
48. Efficacy of [ 67 Cu]Cu-EB-TATE Theranostic Against Somatostatin Receptor Subtype-2-Positive Neuroendocrine Tumors.
49. Effectiveness of 225 Ac-Labeled Anti-EGFR Radioimmunoconjugate in EGFR-Positive Kirsten Rat Sarcoma Viral Oncogene and BRAF Mutant Colorectal Cancer Models.
50. Evaluation of nimotuzumab Fab 2 as an optical imaging agent in EGFR positive cancers.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.